1 Magee J A, Piskounova E, Morrison S J. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell, 2012, 21: 283-296
[2]
2 Nowell P C. Clonal evolution of tumor-cell populations. Science, 1976, 194: 23-28
[3]
3 Baylin S B, Jones P A. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer, 2011, 11: 726-734
[4]
4 Makino S. The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum, 1959, 15: 196-198
[5]
5 Park C H, Bergsage D, Mcculloc E. Mouse myeloma tumor stem cells—primary cell culture assay. J Natl Cancer Inst, 1971, 46: 411-422
[6]
6 Hamburger A, Salmon S E. Primary bioassay of human myeloma stem-cells. J Clin Invest, 1977, 60: 846-854
[7]
7 Reya T, Morrison S J, Clarke M F, et al. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414: 105-111
[8]
8 Morris R J. Keratinocyte stem cells: Targets for cutaneous carcinogens. J Clin Invest, 2000, 106: 3-8
[9]
9 Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal, 2014, 26: 570-579
[10]
10 Wend P, Holland J D, Ziebold U, et al. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol, 2010, 21: 855-863
[11]
11 Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature, 2003, 423: 255-260
[12]
12 Regenbrecht C R A, Lehrach H, Adjaye J. Stemming cancer: Functional genomics of cancer stem cells in solid tumors. Stem Cell Rev, 2008, 4: 319-328
[13]
13 Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid-leukemia after transplantation into scid mice. Nature, 1994, 367: 645-648
[14]
14 Al-Hajj M, Wicha M S, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 2003, 100: 3983-3988
[15]
15 Florek M, Haase M, Marzesco A M, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res, 2005, 319: 15-26
[16]
16 Monzani E, Facchetti F, Galmozzi E , et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer, 2007, 43: 935-946
[17]
17 Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen cd133 (prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells, 2008, 26: 3008-3017
[18]
18 Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract, 2008, 62: 1212-1218
[19]
19 Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133(+) cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA, 2009, 106: 16281-16286
[20]
20 Wang Q, Chen Z G, Du C Z , et al. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology, 2009, 55: 284-293
[21]
21 Ginestier C, Hur M H, Charafe-Jauffret E , et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1: 555-567
[22]
22 Chen Y C, Chen Y W, Hsu H S, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun, 2009, 385: 307-313
[23]
23 Seigel G M, Campbell L M, Narayan M, et al. Cancer stem cell characteristics in retinoblastoma. Mol Vis, 2005, 11: 729-737
[24]
24 Tanei T, Morimoto K, Shimazu K , et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res, 2009, 15: 4234-4241
[25]
25 Gupta P B, Onder T T, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138: 645-659
[26]
26 Creighton C J, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA, 2009, 106: 13820-13825
[27]
27 Liu Y P, Yang C J, Huang M S, et al. Cisplatin selects for multidrug-resistant cd133(+) cells in lung adenocarcinoma by activating notch signaling. Cancer Res, 2013, 73: 406-416
[28]
28 Conley S J, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA, 2012, 109: 2784-2789
[29]
29 Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 2007, 131: 1109-1123
[30]
30 Takebe N, Harris P J, Warren R Q, et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol, 2011, 8: 97-106
[31]
31 Campbell C, Risueno R M, Salati S, et al. Signal control of hematopoietic stem cell fate: Writ, Notch, and Hedgehog as the usual suspects. Curr Opin Hematol, 2008, 15: 319-325
[32]
32 El-Khoueiry A B, Ning Y, Yang D Y, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol, 2013, 31
[33]
33 Gurney A, Axelrod F, Bond C J, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA, 2012, 109: 11717-11722
[34]
34 Schott A F, Landis M D, Dontu G, et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res, 2013, 19: 1512-1524
[35]
35 Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 2006, 444: 1083-1087
[36]
36 Yen W C, Fischer M M, Hynes M, et al. Anti-dll4 has broad spectrum activity in pancreatic cancer dependent on targeting dll4-notch signaling in both tumor and vasculature cells. Clin Cancer Res, 2012, 18: 5374-5386
[37]
37 Singh B N, Fu J, Srivastava R K, et al. Hedgehog signaling antagonist gdc-0449 (vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. Plos One, 2011, 6: e27306
[38]
38 Low J A, de Sauvage F J. Clinical experience with hedgehog pathway inhibitors. J Clin Oncol, 2010, 28: 5321-5326
[39]
55 Wei X, Senanayake T H, Bohling A, et al. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: Synthesis, pharmacokinetics, and tumor growth inhibition. Mol Pharm, 2014, 11: 3112-3122
[40]
56 Swaminathan S K, Roger E, Toti U, et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release, 2013, 171: 280-287
[41]
57 Qiang L, Yang Y, Ma Y J, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett, 2009, 279: 13-21
[42]
58 Jang J Y, Kim M K, Jeon Y K, et al. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med, 2012, 44: 251-259
[43]
59 Yang C, Xiong F, Wang J, et al. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine, 2014, 9: 45-60
[44]
60 Gao X, Luo Y, Wang Y, et al. Prostate stem cell antigen-targeted nanoparticles with dual functional properties: In vivo imaging and cancer chemotherapy. Int J Nanomed, 2012, 7: 4037-4051
[45]
61 Shigdar S, Qiao L, Zhou S F, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett, 2013, 330: 84-95
[46]
62 Lagadinou E D, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell, 2013, 12: 329-341
[47]
63 Phillips T M, McBride W H, Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst, 2006, 98: 1777-1785
[48]
64 Diehn M, Cho R W, Lobo N A, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 2009, 458: 780-783
[49]
65 Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell, 2011, 19: 387-400
[50]
39 Li Y, Zhang T, Korkaya H, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res, 2010, 16: 2580-2590
[51]
40 Kallifatidis G, Labsch S, Rausch V, et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther, 2011, 19: 188-195
[52]
41 Kakarala M, Brenner D E, Korkaya H, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat, 2010, 122: 777-785
[53]
42 Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma a549 cells. Med Chem, 2011, 7: 106-111
[54]
43 Beug H. Breast cancer stem cells: Eradication by differentiation therapy? Cell, 2009, 138: 623-625
[55]
44 Lu D, Choi M Y, Yu J, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA, 2011, 108: 13253-13257
[56]
45 Zhao P, Dong S, Bhattacharyya J, et al. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol Pharm, 2014, 11: 2703-2712
[57]
46 Mimeault M, Johansson S L, Henichart J P, et al. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther, 2010, 9: 617-630
[58]
47 Zhou Y, Yang J, Kope？ek J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials, 2012, 33: 1863-1872
[59]
48 Xu Y, Chenna V, Hu C, et al. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor hpi-1 (nanohhi) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res, 2012, 18: 1291-1302
[60]
49 Chenna V, Hu C, Pramanik D, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (nanohhi) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther, 2012, 11: 165-173
[61]
50 Wu Y, Crawford M, Yu B, et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm, 2011, 8: 1381-1389
[62]
51 Shi S, Han L, Gong T, et al. Systemic delivery of microrna-34a for cancer stem cell therapy. Angew Chem Int Ed, 2013, 52: 3901-3905
[63]
52 Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol, 2013, 31: 577
[64]
53 Liu C, Zhao G, Liu J, et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release, 2009, 140: 277-283
[65]
54 Wei X, Senanayake T H, Warren G, et al. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of cd44-positive and drug-resistant tumors. Bioconjug Chem, 2013, 24: 658-668
[66]
66 Gilbertson R J, Rich J N. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer, 2007, 7: 733-736
[67]
67 Song C W, Park H, Griffin R J. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res, 2001, 155: 515-528
[68]
68 Jones E L, Prosnitz L R, Dewhirst M W, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res, 2004, 10: 4287-4293
[69]
69 Moon E J, Sonveaux P, Porporato P E, et al. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci USA, 2010, 107: 20477-20482
[70]
70 Zhang W, Deng L, Wang G C, et al. Low-magnetization magnetic microcapsules: A synergistic theranostic platform for remote cancer cells therapy and imaging. Part Part Syst Char, 2014, 31: 985-993
[71]
71 Sadhukha T, Niu L, Wiedmann T S, et al. Effective elimination of cancer stem cells by magnetic hyperthermia. Mol Pharm, 2013, 10: 1432-1441
[72]
72 Wang L, Liu Y, Li W, et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: Implications for cancer therapy. Nano Lett, 2011, 11: 772-780
[73]
73 Zhang Z, Wang L, Wang J, et al. Mesoporous silica-coated gold nanorods as a light-mediated multifunctional theranostic platform for cancer treatment. Adv Mater, 2012, 24: 1418-1423
[74]
74 Kang S G, Zhou G, Yang P, et al. Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C-82(OH)22 and its implication for de novo design of nanomedicine. Proc Natl Acad Sci USA, 2012, 109: 15431-15436
[75]
75 Meng J, Liang X, Chen X, et al. Biological characterizations of [Gd@C-82(OH)(22)]n nanoparticles as fullerene derivatives for cancer therapy. Integr Biol (Camb), 2013, 5: 43-47
[76]
76 Wang J, Gu F, Ding T, et al. [Gd@C-82(OH)(22)]n nanoparticles inhibit the migration and adhesion of glioblastoma cells. Oncol Lett, 2010, 1: 771-775
[77]
77 Liu Y, Chen C, Qian P, et al. Gd-metallofullerenol nanomaterial as a non-toxic breast cancer stem cell specific inhibitor. Nat Commun, 2014, 6: 5988
[78]
78 Alakhova D Y, Rapoport N Y, Batrakova E V, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers. J Control Release, 2010, 142: 89-100
[79]
79 Alakhova D Y, Kabanov A V. Pluronics and mdr reversal: An update. Mol Pharm, 2014, 11: 2566-2578
[80]
80 Perera R H, Krupka T M, Wu H, et al. Role of Pluronic block copolymers in modulation of heat shock protein 70 expression. Int J Hyperthermia, 2011, 27: 672-681
[81]
81 Lei T, Fernandez-Fernandez A, Manchanda R, et al. Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating. Beilstein J Nanotechnol, 2014, 5: 313-322
[82]
82 Yoon H J, Kim T H, Zhang Z, et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol, 2013, 8: 735-741
[83]
83 Ding Y P, Ji T J, Song X, et al. Applications of nanotechnology in targeting and regulating the tumor microenvironment. Chin Sci Bull, 2013, 58: 2436-2448
